Lapatinib Resistance in Patients With Breast Cancer

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.

PURPOSE: This research study is looking at lapatinib resistance in patients with breast cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Lapatinib

Criteria

DISEASE CHARACTERISTICS:

• Pathologically confirmed invasive breast cancer

• ErbB2-positive disease

• Has received or is currently receiving lapatinib ditosylate

• Documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration OR a radiographic response)

• Must have tumor tissue samples available for research studies

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Not pregnant*

• Coagulation profile normal*

• Platelet count > 100,000/mm³* NOTE: *For patients requiring a post-treatment biopsy

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Concurrent chemotherapy or trastuzumab (Herceptin®) allowed

• No concurrent anticoagulants, including warfarin or low-molecular weight heparin*

• No concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents* NOTE: *For patients requiring a post-treatment biopsy